In Depth 19 Jan 2024
Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?
Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.
About
Graduated with a degree in BA Journalism from the University of South Wales (Cardiff) in 2021. Shortly afterwards, I fell into content writing for a couple of different companies writing about different subjects including science, tech, crypto, lifestyle etc. But journalism is where my heart truly lies, and just before I landed my role here, I did a journalism internship with an online publication called TheSocialTalks, where I finally had an opportunity to get my journalistic work published. The rest is history and, having always been interested in biology and medical science, I’m now living my dream as a junior reporter here at Labiotech. Outside of work, hobbies include reading, TV & Film, cooking, travelling, eating out, and a decent amount of wine tasting…
Articles by Willow Shah-Neville
Best in Biotech 16 Jan 2024
Five biotech companies taking Florida by storm
Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies.
In Depth 10 Jan 2024
The biggest private biotech investments in December 2023
The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players attracted the biggest funding rounds overall. Although December is generally a quiet time for biotech fundraising, there were still some big rounds raised in the […]
Best in Biotech 21 Dec 2023
Five companies racing to bring their NASH treatments toward the finish line
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or cirrhosis. With no U.S. Food and Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a […]
In Depth 13 Dec 2023
Revolutionizing glioblastoma treatment: how CAR-T cell therapy could be used as a cure
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could be used to cure glioblastoma.
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
ADVERTISEMENT
ADVERTISEMENT
In Depth 7 Dec 2023
The biggest private biotech investments in November 2023
The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]
News and Trends 6 Dec 2023
A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy
Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]
Best in Biotech 28 Nov 2023
Five companies shaping Texas’ growing biotech hubs
Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […]
In Depth 22 Nov 2023
Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment
Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]
Best in Biotech 21 Nov 2023
Beyond insulin: six cutting-edge diabetes biotech companies you should know about
As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […]
In Depth 16 Nov 2023
Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again
Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]
ADVERTISEMENT
